Navigation Links
Growth in the Parkinson's Disease Drug Market, Fueled by the Launch of Several New Therapies, Will be Offset by Generic Erosion of Key Agents
Date:6/9/2009

Overall Market Will Increase by a Modest $300 Million From 2008 to 2018, According to a New Report from Decision Resources

WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that growth in the Parkinson's disease drug market, fueled by the launch of several new therapies through 2018, will be offset by generic erosion of key currently-available agents. As a result, sales of Parkinson's disease therapies will increase modestly from $2.5 billion in 2008 to $2.8 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Parkinson's Disease finds that the majority of market sales will continue to be driven by the dopamine agonist drug class that includes Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol, GlaxoSmithKline's Requip, GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutab and UCB/Schwarz Pharma's Neupro. However, sales of some of these agents, including Mirapex/Mirapexin/Sifrol and Requip XL/LP/RP/Modutab, will be offset by increased uptake of generic equivalents. Market growth will also be constrained by the generic erosion of other key therapies, including Novartis/Orion Pharma's Comtan/Comtess/Stalevo and Teva Pharmaceuticals/Lundbeck's Agilect/Azilect.

According to the report, market sales will also be driven by the emergence of novel agents, most notably Merck Serono/EMD Serono/Newron Pharmaceuticals' safinamide, Solvay Pharmaceuticals' pardoprunox, and Acadia Pharmaceuticals/Biovail Pharmaceuticals' pimavanserin, which will be used to treat niche Parkinson's disease populations.

The report also finds that the results of recent key clinical trials will affect the way clinicians treat patients with early Parkinson's disease.

"The results of the ADAGIO trial demonstrated the dis
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. High pollution linked to poor lung function growth in children in Mexico City
2. Researchers develop long-lasting growth hormone
3. Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
4. Plexus Systems Ranks in Top Third of the 2007 Inc. 5,000 with Three-Year Sales Growth of 226%
5. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
6. AWT Management Announce Aggressive Growth and Acquisition Strategy
7. Cynosure to Present at the Maxim Group Growth Conference
8. Human C-reactive protein regulates myeloma tumor cell growth and survival
9. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
10. Cepheid to Present at ThinkEquity Partners 5th Annual Growth Conference
11. Spectranetics to Present at The A.G Edwards Growth Conference on September 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2012)... (May 22, 2012) Scientists at Virginia Commonwealth ... closer to developing a new therapy for acute ... agents obatoclax and sorafenib kill leukemia cells much ... are administered individually., Recently published in the journal ... Steven Grant, M.D., Shirley Carter Olsson and Sture ...
(Date:5/22/2012)... 2012) Pushed to the brink of survival, the ... ancient system that has helped organisms cope with internal ... an integral part of this system, heat shock protein ... accommodate the genetic changes and profound disturbances in normal ... theorized that inhibiting HSP90 just might render breast cancer ...
(Date:5/22/2012)... PORTLAND, Ore. Women who are unable to ... lung function of their newborns by taking Vitamin ... Oregon Health & Science University Doernbecher Children,s Hospital. ... affect the lung development of the developing baby, ... risk of asthma," said Cindy McEvoy, M.D., M.C.R., ...
(Date:5/22/2012)... May 22 (HealthDay News) -- The number of liver ... a new study finds. Researchers said one reason ... death has become more commonplace, and many of those ... organs aren,t healthy enough to attempt a transplant. Another ... to a condition known as fatty liver disease, which ...
(Date:5/22/2012)... microfluidic chip to test for latent tuberculosis. They hope ... than current testing for the disease. , "Our assay ... said Ying Liu, a research specialist working with Professor ... Engineering. , The team has already conducted testing of ... States. , About one-third of the world,s population is ...
Breaking Medicine News(10 mins):Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 2Health News:VCU Massey Cancer Center sees potential in novel leukemia treatment 3Health News:Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy 2Health News:Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy 3Health News:Vitamin C improves lung function in newborns of pregnant smoking women 2Health News:U.S. Liver Transplants Declining 2Health News:New TB test promises to be cheap and fast 2
... Researchers in Germany have developed a new risk assessment ... and patient's risk of cardiac death. , ECG is ... death can be determined and analysed by the computer.The ... to be calculated.// When the programme has completed its ...
... Researchers in France say that the distorting spectacles can ... balance. They think that the spectacles reset the patient's ... to a long-lasitng cure for some postural problems. ... hemisphere may suffer paralysis down their left side and ...
... of starch, previously thought to be just 'empty calories', actually ... Research Organisation (CSIRO), researchers have revealed that resistant starch could ... cancer. , , ... and China have low rates of bowel cancer even though ...
... has now been developed, which makes the process of providing ... , , The device, called Percutaneous ... involves giving artificial respiration to critically ill patients.// , ... the wall of the trachea,the passage leading to the lungs, ...
... is linked with deliquent behaviour of the chilren later ... Delaney-Black, of Children's Hospital of Michigan, the co author ... in comparison to the teetotallers ,women who drank the ... three times more likely to have a child diagnosed ...
... by the National Institutes of Health, showed that at-risk ... reduced their risk of diabetes by 58%, even without ... type 2 diabetes can sharply reduce the odds through ... data from the nation's first major clinical trial to ...
Other Medicine News:
(Date:5/22/2012)... -- Comprehensive Care Corporation ("CompCare") (OTC BB: CHCR), a ... management services provider for managed care companies throughout ... the first quarter of 2012 ending March 31, ... the quarter. "We are pleased ... modest, for its first quarter of 2012.  This ...
(Date:5/22/2012)... May 22, 2012  Based on its recent ... Sullivan recognizes Labcyte Inc. with the 2012 North ... liquid handler. While various liquid handling technologies provide ... range of advantages provided by the Echo liquid ... handling, Labcyte developed a platform enabling assay miniaturization ...
(Date:5/22/2012)... GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical ... Immunodeficiency Virus (HIV) infections, today announced that the ... enrollment for a Phase 1 trial for the ... identical to the first generation (currently ... the inclusion of granulocyte-macrophage colony-stimulating factor (GM-CSF) as ...
Breaking Medicine Technology:Comprehensive Care Corporation Announces Profit for First Quarter 2Comprehensive Care Corporation Announces Profit for First Quarter 3Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 2Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 3Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 4Frost & Sullivan Recognizes Labcyte for its Commitment to Innovation and Addressing Unmet Needs in the Liquid Handling Market 5HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine 2HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine 3HIV Vaccine Trials Network Opens Enrollment for Phase 1 Trial of GeoVax Labs' Second Generation HIV Vaccine 4 Some Folks Just Cant Help Being Nice Study Suggests 90172 1 Some Folks Just Cant Help Being Nice Study Suggests 90172 2Power without the cord 90168 1Power without the cord 90168 2Power without the cord 90168 3AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards 90164 1AFAR announces the 2012 Hartford Centers of Excellence in Geriatric Medicine awards 90164 2
... 12 Lixte,Biotechnology Holdings, Inc. (OTC Bulletin Board: ... application for the use of compounds the company,is ... treatments for,neurodegenerative diseases including Alzheimer,s and Parkinson,s Disease., ... of Lixte, said, "Lixte has,developed a series of ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ) ... pivotal studies evaluating Viprinex(TM) (ancrod) for,the treatment of ... patients,necessary to conduct a planned interim analysis across ... is safe and effective for treating,acute ischemic stroke ...
Other Medicine Technology:Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases 2Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials 2Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials 3
Angled 30 degree shaft. 13 mm from tip to bend with 2.5 mm hook curved tip. Polished finished. Overall length excluding hub: 35 mm, 1.4 inches....
Binkhorst, length 18 mm....
Army/Navy retractor (set of 2)....
Sharp. 4 mm wide. Hand-Held...
Medicine Products: